← Leaderboards
Thales Papagiannakopoulos
New York University School Of Medicine
$8,767,709
Attributed
$9,115,993
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2016–25$2.5M$1.9M$1.3M$625K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,115,993 · 6
By mechanism
R01$5,286,673 · 4
R37$3,259,080 · 1
K22$570,240 · 1
Top collaborators
- Shohei Koide1 shared
Most similar at New York University School Of Medicine
Same institution · by research overlap
- Benjamin G. Neel$33,134,772
- Kwok Kin Wong$31,472,345
- Dan R Littman$30,444,906
- Kari E Hacker$1,374,992
- Chao Lu$7,221,423
Others in their field
Top investigators on “Response”
- Lawrence Corey · Fred Hutchinson Cancer Center$677,505,141
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$532,027,174
- Barton F Haynes · Duke University$497,761,007
- Jeffrey P Krischer · University Of South Florida$397,532,270
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
Research focus
ResponseGenetically Engineered MouseCrispr/Cas TechnologyMutationGeneticCellsNon-Small-Cell Lung CarcinomaTumorSolid NeoplasmTechnologyMalignant Neoplasm Of LungLung AdenocarcinomaAntioxidantsLoss Of Function MutationMetabolismPathway InteractionsProgramsMetabolicNovel Therapeutic InterventionMutantKras2 GeneVirtualClinical OncologyGenotype
Grant awards (20)
Targeting LCN2, a novel therapy for lung cancer$696,569
R01 · FY2025 · CA · contact PI
Novel approaches to target KEAP1 mutant tumors$658,687
R01 · FY2025 · CA · contact PI
Investigating the therapeutic potential of a novel glutamine antagonist in KEAP1 mutant lung cancer$655,478
R01 · FY2025 · CA · contact PI
Novel approaches to target KEAP1 mutant tumors$676,063
R01 · FY2024 · CA · contact PI
Investigating the therapeutic potential of a novel glutamine antagonist in KEAP1 mutant lung cancer$672,853
R01 · FY2024 · CA · contact PI
Identifying metabolic dependencies in genetic subtypes of KRAS-driven lung cancer$449,392
R37 · FY2024 · CA · contact PI
Identifying metabolic dependencies in genetic subtypes of KRAS-driven lung cancer$463,583
R37 · FY2023 · CA · contact PI
Identifying metabolic dependencies in genetic subtypes of KRAS-driven lung cancer$473,044
R37 · FY2022 · CA · contact PI
Uncovering Genotype Specific Vulnerabilities in KRAS Mutant Lung Cancer?$387,731
R01 · FY2022 · CA · contact PI
Identifying metabolic dependencies in genetic subtypes of KRAS-driven lung cancer$473,044
R37 · FY2021 · CA · contact PI
Uncovering Genotype Specific Vulnerabilities in KRAS Mutant Lung Cancer?$387,731
R01 · FY2021 · CA · contact PI
Identifying metabolic dependencies in genetic subtypes of KRAS-driven lung cancer$473,044
R37 · FY2020 · CA · contact PI
Uncovering Genotype Specific Vulnerabilities in KRAS Mutant Lung Cancer?$387,731
R01 · FY2020 · CA · contact PI
Identifying metabolic dependencies in genetic subtypes of KRAS-driven lung cancer$458,853
R37 · FY2019 · CA · contact PI
Uncovering Genotype Specific Vulnerabilities in KRAS Mutant Lung Cancer?$376,099
R01 · FY2019 · CA · contact PI
Identifying metabolic dependencies in genetic subtypes of KRAS-driven lung cancer$468,120
R37 · FY2018 · CA · contact PI
Uncovering Genotype Specific Vulnerabilities in KRAS Mutant Lung Cancer?$387,731
R01 · FY2018 · CA · contact PI
Elucidating the role of the Nrf2 anti-oxidant pathway in lung adenocarcinoma$190,080
K22 · FY2018 · CA · contact PI
Elucidating the role of the Nrf2 anti-oxidant pathway in lung adenocarcinoma$190,080
K22 · FY2017 · CA · contact PI
Elucidating the role of the Nrf2 anti-oxidant pathway in lung adenocarcinoma$190,080
K22 · FY2016 · CA · contact PI